160 related articles for article (PubMed ID: 28655783)
21. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
22. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.
Kach J; Long TM; Selman P; Tonsing-Carter EY; Bacalao MA; Lastra RR; de Wet L; Comiskey S; Gillard M; VanOpstall C; West DC; Chan WC; Griend DV; Conzen SD; Szmulewitz RZ
Mol Cancer Ther; 2017 Aug; 16(8):1680-1692. PubMed ID: 28428441
[TBL] [Abstract][Full Text] [Related]
23. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer.
Dahiya NR; Chandrasekaran B; Kolluru V; Ankem M; Damodaran C; Vadhanam MV
Mol Carcinog; 2018 Oct; 57(10):1332-1341. PubMed ID: 30069922
[TBL] [Abstract][Full Text] [Related]
24. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.
Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z
Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604
[TBL] [Abstract][Full Text] [Related]
25. Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain.
Peng S; Wang J; Chen H; Hu P; He XL; He Y; Wang M; Tang W; He Q; Wang YY; Xie J; Guo D; Ren S; Liu M; Qiu WW; Yi Z
Cell Biol Toxicol; 2020 Oct; 36(5):399-416. PubMed ID: 32002708
[TBL] [Abstract][Full Text] [Related]
26. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
27. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
[TBL] [Abstract][Full Text] [Related]
28. Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
Oksala R; Moilanen A; Riikonen R; Rummakko P; Karjalainen A; Passiniemi M; Wohlfahrt G; Taavitsainen P; Malmström C; Ramela M; Metsänkylä HM; Huhtaniemi R; Kallio PJ; Mustonen MV
J Steroid Biochem Mol Biol; 2019 Sep; 192():105115. PubMed ID: 29438723
[TBL] [Abstract][Full Text] [Related]
29. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
30. Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.
Shih TC; Liu R; Wu CT; Li X; Xiao W; Deng X; Kiss S; Wang T; Chen XJ; Carney R; Kung HJ; Duan Y; Ghosh PM; Lam KS
Clin Cancer Res; 2018 Sep; 24(17):4319-4331. PubMed ID: 29666302
[No Abstract] [Full Text] [Related]
31. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
[TBL] [Abstract][Full Text] [Related]
32. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.
Rasool RU; Natesan R; Deng Q; Aras S; Lal P; Sander Effron S; Mitchell-Velasquez E; Posimo JM; Carskadon S; Baca SC; Pomerantz MM; Siddiqui J; Schwartz LE; Lee DJ; Palanisamy N; Narla G; Den RB; Freedman ML; Brady DC; Asangani IA
Cancer Discov; 2019 Nov; 9(11):1538-1555. PubMed ID: 31466944
[TBL] [Abstract][Full Text] [Related]
33. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
34. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.
Li H; Xie N; Gleave ME; Dong X
Oncotarget; 2015 Aug; 6(24):20474-84. PubMed ID: 26009876
[TBL] [Abstract][Full Text] [Related]
35. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
36. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
37. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.
Wu M; Kim SH; Datta I; Levin A; Dyson G; Li J; Kaypee S; Swamy MM; Gupta N; Kwon HJ; Menon M; Kundu TK; Reddy GP
Oncotarget; 2015 Mar; 6(8):6136-50. PubMed ID: 25704883
[TBL] [Abstract][Full Text] [Related]
38. A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer.
Yang Z; Wang D; Johnson JK; Pascal LE; Takubo K; Avula R; Chakka AB; Zhou J; Chen W; Zhong M; Song Q; Ding H; Wu Z; Chandran UR; Maskrey TS; Nelson JB; Wipf P; Wang Z
Mol Cancer Ther; 2020 Jan; 19(1):75-88. PubMed ID: 31554654
[TBL] [Abstract][Full Text] [Related]
39. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
40. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
